Tuesday, April 09, 2024 12:03:59 AM
Recent CLDI News
- Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting • Business Wire • 05/01/2024 11:00:00 AM
- Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 • Business Wire • 04/23/2024 11:00:00 AM
- Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering • Business Wire • 04/19/2024 08:05:00 PM
- Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering • Business Wire • 04/16/2024 12:31:00 PM
- Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024 • Business Wire • 04/09/2024 11:00:00 AM
- Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results • Business Wire • 03/15/2024 08:05:00 PM
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer • Business Wire • 03/11/2024 11:00:00 AM
- Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference • Business Wire • 02/12/2024 12:00:00 PM
- Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board • Business Wire • 01/08/2024 12:00:00 PM
- Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit • Business Wire • 12/13/2023 12:00:00 PM
- Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors • Business Wire • 12/12/2023 12:00:00 PM
- Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones • Business Wire • 11/20/2023 12:00:00 PM
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results • Business Wire • 11/14/2023 09:05:00 PM
- Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023) • Business Wire • 11/03/2023 11:00:00 AM
- Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment • Business Wire • 11/01/2023 11:00:00 AM
- Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer • Business Wire • 10/30/2023 11:00:00 AM
- Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023 • Business Wire • 10/10/2023 11:00:00 AM
- Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies • Business Wire • 09/13/2023 09:50:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM